Progress in pharmacogenomics: Bridging the gap from research to practice

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 3, 2014, Pages 231-235

  Cascorbi, I ^a   Tyndale, R ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASES; EPIGENESIS, GENETIC; GENE-ENVIRONMENT INTERACTION; HUMANS; NEOPLASMS; ORGAN TRANSPLANTATION; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOKINETICS; PROFESSIONAL PRACTICE; PSYCHIATRY; RESEARCH;

EID: 84894431803     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.235     Document Type: Review

References (24)

1. Relling, M.V. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin. Pharmacol. Ther. 93, 324-325 (2013).
2. Roden, D.M. & Tyndale, R.F. Genomic medicine, precision medicine, personalized medicine: what's in a name? Clin. Pharmacol. Ther. 94, 169-172 (2013).
3. Kalow, W. Pharmacogenetics in biological perspective. Pharmacol. Rev. 49, 369-379 (1997).
4. Wang, D., Guo, Y., Wrighton, S.A., Cooke, G.E. & Sadee, W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11, 274-286 (2011).
5. Zanger, U.M. et al. Genetics, epigenetics, and regulation of drug-metabolizing cytochrome P450 enzymes. Clin. Pharmacol. Ther. 95, 258-261 (2014).
6. McDermott, U., Downing, J.R. & Stratton, M.R. Genomics and the continuum of cancer care. N. Engl. J. Med. 364, 340-350 (2011).
7. Turner, R.M. & Pirmohamed, M. Cardiovascular pharmacogenomics: expectations and practical benefits. Clin. Pharmacol. Ther. 95, 281-293 (2014).
8. Perera, M.A., Cavallari, L.H. & Johnson, J.A. Warfarin pharmacogenetics: an illustration of why studies in minority populations are important. Clin. Pharmacol. Ther. 95, 242-244 (2014).
9. Pirmohamed, M. et al. A randomized trial of genotypeguided dosing of warfarin. N. Engl. J. Med. 369, 2294-2303 (2013).
10. Kimmel, S.E. et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369, 2283-2293 (2013).
11. Schwarz, U.I. et al. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358, 999-1008 (2008).
12. Takeuchi, F. et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, e1000433 (2009).
13. Perera, M.A. et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 382, 790-796 (2013).
14. Jamshidi, Y. et al. Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. J Am. Coll. Cardiol. 60, 841-850 (2012).
15. van Gelder, T., van Schaik, R.H. & Hesselink, D.A. Practicability of pharmacogenetics in transplantation medicine. Clin. Pharmacol. Ther. 95, 262-264 (2014).
16. Barry, A. & Levine, M. A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients. Ther. Drug Monit. 32, 708-714 (2010).
17. Press, R.R., de Fijter, J.W. & Guchelaar, H.J. Individualizing calcineurin inhibitor therapy in renal transplantation -current limitations and perspectives. Curr. Pharm. Des. 16, 176-186 (2010).
18. Crettol, S., de Leon, J., Hiemke, C. & Eap, C.B. Pharmacogenomics in psychiatry: from therapeutic drug monitoring. Clin. Pharmacol. Ther. 95, 254-257 (2014).
19. Pacanowski, M.A., Leptak, C. & Zineh, I. Nextgeneration medicines: past regulatory experience and considerations for the future. Clin. Pharmacol. Ther. 95, 247-249 (2014).
20. Daly, A.K. Is there a need to teach pharmacogenetics? Clin. Pharmacol. Ther. 95, 245-247 (2014).
21. Gillis, N.K., Patel, J.N. & Innocenti, F. Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin. Pharmacol. Ther. 95, 269-280 (2014).
22. Ulahannan, D., Kovac, M.B., Mulholland, P.J., Cazier, J.B. & Tomlinson, I. Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. Br. J. Cancer 109, 827-835 (2013).
23. Rosell, R., Bivona, T.G. & Karachaliou, N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382, 720-731 (2013).
24. Bendtzen, K. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. Discov. Med. 15, 201-211 (2013).